PT - JOURNAL ARTICLE AU - MARKO LUCIJANIC AU - DAVID CICIC AU - TAJANA STOOS-VEIC AU - VLATKO PEJSA AU - JELENA LUCIJANIC AU - AMINA FAZLIC DZANKIC AU - JOSIPA VLASAC GLASNOVIC AU - ENA SORIC AU - MARKO SKELIN AU - RAJKO KUSEC TI - Elevated Neutrophil–to–Lymphocyte-ratio and Platelet–to–Lymphocyte Ratio in Myelofibrosis: Inflammatory Biomarkers or Representatives of Myeloproliferation Itself? DP - 2018 May 01 TA - Anticancer Research PG - 3157--3163 VI - 38 IP - 5 4099 - http://ar.iiarjournals.org/content/38/5/3157.short 4100 - http://ar.iiarjournals.org/content/38/5/3157.full SO - Anticancer Res2018 May 01; 38 AB - Background/Aim: We aimed to investigate clinical associations of inflammatory biomarkers neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in patients with myelofibrosis, myeloproliferative neoplasm with inflammatory background. Patients and Methods: We retrospectively analyzed a cohort of 102 myelofibrosis patients. NLR and PLR were assessed in addition to other disease-specific parameters. Results: NLR and PLR were significantly higher in myelofibrosis than in healthy controls. Higher NLR was significantly associated with Janus-kinase-2 (JAK2)-mutation, wild-type-Calreticulin (CALR), older age and parameters reflecting increased proliferative potential of disease (higher leukocytes, higher hemoglobin, larger spleen-size), whereas there was no significant association with C-reactive-protein (CRP). Higher PLR was significantly associated with absence of blast-phase-disease, absence of constitutional-symptoms, lower percentage-of-circulatory-blasts, smaller spleen-size and lower CRP. In the Cox-regression-model, higher-NLR (HR=2.76; p=0.004), lower-PLR (HR=1.99; p=0.042) and Dynamic-International-Prognostic-System (DIPSS) (HR=3.26; p<0.001) predicted inferior survival independently of each other. Conclusion: In the context of myelofibrosis, elevated NLR and PLR are more likely to represent myeloproliferation itself and not necessary the extent of inflammation.